Search research articles
Contact Us
Filters
Showing results (111-120 of 261) with videos related to
Page
of 27
Sort By:
Journal of Hepatology
|
May 26, 2026
EASL position paper on preclinical models of steatotic liver disease
Suchira Gallage, Rui E Castro, Jennifer Estall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 24, 2018
Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation
Yvonne Huber, Marie Boyle, Kate Hallsworth, et al.
JHEP Reports : Innovation in Hepatology
|
May 22, 2020
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
Lorraine McSweeney, Matthew Breckons, Gulnar Fattakhova, et al.
BMJ Open
|
March 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
Neeta B Amin, Amanda Darekar, Quentin M Anstee, et al.
Journal of Hepatology
|
December 7, 2023
NIS2+<sup>TM</sup> as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials
Vlad Ratziu, Stephen A Harrison, Yacine Hajji, et al.
Journal of Hepatology
|
July 16, 2011
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies
Ahmad Al-Serri, Quentin M Anstee, Luca Valenti, et al.
Artificial Organs
|
May 12, 2022
Pharmacological testing of therapeutics using normothermic machine perfusion: A pilot study of 2,4-dinitrophenol delivery to steatotic human livers
Samuel J Tingle, Emily R Thompson, Lucy Bates, et al.
Biochemical Pharmacology
|
May 2, 2024
Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment
Olivier Govaere, Simon J Cockell, Michalina Zatorska, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 23, 2014
The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity
Lucia A Possamai, Mark Jw McPhail, Wafa Khamri, et al.
Nature Reviews. Gastroenterology & Hepatology
|
September 11, 2021
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Mojgan Masoodi, Amalia Gastaldelli, Tuulia Hyötyläinen, et al.
Page
of 27
Search research articles
Search
Showing results (111-120 of 261) with videos related to
Sort By:
Page
of 27
Journal of Hepatology
|
May 26, 2026
EASL position paper on preclinical models of steatotic liver disease
Suchira Gallage, Rui E Castro, Jennifer Estall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 24, 2018
Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation
Yvonne Huber, Marie Boyle, Kate Hallsworth, et al.
JHEP Reports : Innovation in Hepatology
|
May 22, 2020
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
Lorraine McSweeney, Matthew Breckons, Gulnar Fattakhova, et al.
BMJ Open
|
March 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
Neeta B Amin, Amanda Darekar, Quentin M Anstee, et al.
Journal of Hepatology
|
December 7, 2023
NIS2+<sup>TM</sup> as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials
Vlad Ratziu, Stephen A Harrison, Yacine Hajji, et al.
Journal of Hepatology
|
July 16, 2011
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies
Ahmad Al-Serri, Quentin M Anstee, Luca Valenti, et al.
Artificial Organs
|
May 12, 2022
Pharmacological testing of therapeutics using normothermic machine perfusion: A pilot study of 2,4-dinitrophenol delivery to steatotic human livers
Samuel J Tingle, Emily R Thompson, Lucy Bates, et al.
Biochemical Pharmacology
|
May 2, 2024
Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment
Olivier Govaere, Simon J Cockell, Michalina Zatorska, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 23, 2014
The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity
Lucia A Possamai, Mark Jw McPhail, Wafa Khamri, et al.
Nature Reviews. Gastroenterology & Hepatology
|
September 11, 2021
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Mojgan Masoodi, Amalia Gastaldelli, Tuulia Hyötyläinen, et al.
Page
of 27